Medical School
Department of Medicine

Physician-Scientist Training Program

Kurt Prins 

Education & Training 

B.S., Exercise Physiology — University of Wisconsin, Madison

M.D., Ph.D., Biochemistry, Molecular Biology, and Biophysics
— University of Minnesota

Internal Medicine Residency 
 University of Alabama, Birmingham

Cardiology Fellowship 
 — University of Minnesota 

Honors & Awards

  • Faculty appointment, University of Minnesota Cardiovascular Division

  • Mentored Clinical Scientist Research Career Development Award (K08): Mechanisms of Juntophilin-2 Misregulation that Contribute to Right Ventricular Dysfunction in Pulmonary Arterial Hypertension, mentor Joseph Metzger, 2018-2023

  • National Heart, Blood, and Lung Institute Ruth L Kirschstein National Research Service Award (F32): Investigating Microtubules in Duchenne Cardiomyopathy, mentor Joseph Metzger, 2015-2018

  • Best Basic Science Presentation, Pulmonary Vascular Research Institute (PVRI) Annual Conference, 2017


Dr. Prins' research involves investigating the role of the microtubule cytoskeleton in cardiovascular diseases. He is also actively pursuing a multi-disciplinary approach to pulmonary hypertension to better understand the pathogenesis, identify screening tools, and hopefully develop new treatments for this devastating disease.  


  1. K.W. Prins, L. Rose, S.L. Archer, M. Pritzker, E.K. Weir, F. Kamirczak, J.R. Misialek, T. Thenappan. 2018. Disproportionate right ventricular dysfunction and poor survival in group 3 pulmonary hypertension. Am. J. Respir. Crit. Care Med. Jan 23 [epub ahead of print]
  2. K.W. Prins, S.L. Archer, M. Pritzker, L. Rose, E.K. Weir, A. Sharma, T. Thenappan. 2018. Interleukin-6 is independently associated with right ventricular function in pulmonary arterial hypertension. J. Heart Lung Transplant  37(3):376-384.
  3. K.W. Prins, L. Tian, D. Wu, T. Thenappan, J.M. Metzger, S.L. Archer. 2017. Colchine Depolymerizes Microtubules, Increases Junctophilin-2, and Improves Right Ventricular Function in Experimental Pulmonary Arterial Hypertension. J. Am. Heart Assoc. 6(6):e006023.
  4. K.W. Prins, S. Duval, J. Markowitz, M. Pritzker, T. Thenappan. 2017. Chronic use of PAH-specific therapy in World Health Organization Group III Pulmonary Hypertension: a systematic review and meta-analysis. Pulm. Circ. 7(1):145-155.
  5. K.W. Prins, E.K. Wieir, S.L. Archer, J. Markowitz, L. Rose, M. Pritzker, R. Madlon-Kay, T. Thenappan. 2016. Pulmonary pulse wave transit time is associated with right ventricular-pulmonary artery coupling in arterial hypertension. Pulm. Circ. 6(4):576-85.
  6. K.W. 

    Prins, M. Asp, H. Zhang, W. Wang, J. Metzger. 2016. Microtubule-mediated Misregulation of Junctophilin-2 Underlies T-tubule Disruptions and Calcium Mishandling in Mdx Mice.  JACC Basic Transl. Science 3:122-30.

  7. K.W. Prins, T. Thenappan. World Health Organization Group I Pulmonary Hypertension: Epidemiology and Pathophysiology. 2016. Cardiol. Clin. 34(3):363-74
  8. T. Thenappan, K.W. Prins, M. Pritzker, J. Scandurra, K. Volmers, E. Weir. 2016. The Critical Role of Pulmonary Arterial Compliance in Pulmonary HypertensionAnn. Am. Thorac. Sci. 2:276-284.

  9. K.W. Prins, T. Thenappan, J. Markowitz, and M. Pritzker. 2015. Cardiorenal Syndrome Type 1: renal dysfunction in acute decompensated heart failureJ. Clin. Outcomes Mange. 22(10):443-54.  
  10. K.W. Prins, J.O. Neill, J.O. Tyler, P.M. Eckman, S. Duval. 2015. Effects of b-blocker withdrawal in acute decompensated heart failure: A systematic review and meta-analysis. JCHF 8:647-653.
  11. T. Thenappan, K.W. Prins, R. Cogswell, S. Shah. 2015. Pulmonary hypertension secondary to heart failure with preserved ejection fraction.  Can. J. Cardiol. 4:430-439.
  12. K.W. Prins., K.M. Wille, J. Tallaj, A.J. Tolwani. 2015. Assessing continuous renal replacement therapy as a rescue strategy in cardiorenal syndrome 1Clin. Kidney J. 8 (1):87-92.
  13. K. Prins, C. Masri, M. Colvin-Adams, P.M. Eckman. 2013. Characterization of 25+ year survivors of cardiac transplantationJHLT 32:560-562.
  14. K.W. Prins, J.A. Call, D.A. Lowe, J.M. Ervasti. 2011. Quadriceps myopathy caused by skeletal muscle specific ablation of bcyto-actin.  J. Cell Sci. 124:951-957.
  15. K.W. Prins, J.L. Humston, A. Mehta, V. Tate, E. Ralston, J.M. Ervasti. 2009.  Dystrophin is a microtubule-associated proteinJ.Cell Biol. 186:363-369.
  16. M.A. Jaeger, K.J. Sonnemann, D.P. Fitzsimons, K.W. Prins, J.M. Ervasti. 2009. Context-dependent functional substitution of alpha-skeletal actin by gamma-cytoplasmic actin. FASEB J. 23:2205-2214.
  17. T.M. Bunnell, M.A. Jaeger, D.P. Fitzsimons, K.W. Prins, J.M. Ervasti. 2008. Destabilization of the dystrophin-glycoprotein complex without functional deficits in alpha-dystrobrevin null musclePLoS ONE 3(7):e2604.
  18. K.W. Prins, D.A. Lowe, J.M. Ervasti. 2008. Skeletal muscle-specific ablation of gamma(cyto)-actin does not exacerbate the mdx phenotypePLoS ONE 3(6):e2419.

New Research Featured

posted Jul 21, 2017, 6:06 AM by Sarah Sexton   [ updated Jul 21, 2017, 6:09 AM ]

Kurt's JAMA article on colchicine was highlighted on the Medical School's home page in the news item Everything Old is New Again in June 2017.

The Pulse Spotlight: Kurt Prins

posted Nov 11, 2015, 6:05 AM by Sarah Sexton

Kurt Prins was featured in The Pulse Cardiovascular Fellowship Newsletter for Fall 2015:

Since returning to the University of Minnesota afer 2 years of residency at UAB (Prins completed Medical School and received his PhD at University of Minnesota), Kurt has been outstanding. He has numerous publications since starting fellowship, and was awarded a F32 grant from the NIH which started this July. This grant, “Investigating the role of microtubules in Duchenne Cardiomyopathy” under the mentorship of Dr. Joseph Metzger. His clinical plans are to pursue an advanced fellowship in Heart Failure. His clinical mentor, Dr. Tenappan Tenappan describes him as “hard working, dedicated, thorough and innovative.” Kurt has made great progress so far and we can’t wait to see what he does next!

Featured in HealthTalk Research Spotlight

posted Aug 14, 2015, 12:31 PM by Sarah Sexton   [ updated Aug 25, 2015, 8:34 AM ]

Kurt Prins' recent study in the Journal of the American College of Cardiology-Heart Failure is featured in the HealthTalk blog Research SnapshotEffects of beta-blocker withdrawal in acute decompensated heart failure

"The implications for our study are patients with ADHF should have their beta-blocker continued if possible because it may reduce the risk of adverse events. Going forward, we hope more physicians will continue beta-blockers in ADHF patients.”

Study published in J Am Coll Cardiol

posted Aug 14, 2015, 12:30 PM by Sarah Sexton   [ updated Aug 25, 2015, 8:35 AM ]

Kurt Prins is the lead author of a recent study in the Journal of the American College of Cardiology-Heart Failure, "Effects of Beta-Blocker Withdrawal in Patients Admitted with Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis." 

The study was a collaborative project between physicians and statisticians, examining three outcomes of stopping the beta-blockers: in-hospital mortality, short-term mortality and combined short-term mortality and rehospitalization. Although it is unknown how beta-blocker withdrawal directly causes harm to the heart, all three endpoints were associated with worse outcomes when beta-blockers were stopped.

1-4 of 4